Alchemab Therapeutics Ltd: Valuation, Funding & Investors
Alchemab Therapeutics Ltd is a biotechnology company that discovers and develops therapeutic antibodies by mining human immune repertoires and identifying naturally occurring, disease-protective immune responses. The company combines systems immunology, computational analysis, and experimental validation to translate protective antibody signatures into diagnostic tools and monoclonal antibody therapeutics across multiple disease areas.
Leadership & Board
Key Executives
- Founder
- Jane Osbourn OBE
- Founder
- Rachael Bashford-Rogers
- Current Number of Employees
- 74
- Current LinkedIn Followers
- 12,402
Latest Estimated Valuation
- Total Amount Raised
- $65M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $33M
- Latest Funding Round
- Series A
Company Momentum
PositiveAlchemab Therapeutics Ltd LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Alchemab Therapeutics Ltd had 74 employees as of November 9, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Alchemab Therapeutics Ltd had 12,402 followers as of November 9, 2026. The number of followers increased by 36 (0.29%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 15, 2026 | Series A | $33.00M | ― |
| Oct 09, 2025 | Series A | $32.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Ono Venture Investment | Series A |
Similar Companies
A snapshot of private companies similar to Alchemab Therapeutics Ltd, helping you discover and navigate related company profiles.
